Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies
Despite multiple available agents and combinations, effective treatment of all patients with relapsed/refractory multiple myeloma remains a major unmet need. Given their distinct mechanism of action, immunotherapies hold significant potential to address this gap and improve clinical outcomes.
Authors
- Paola La Malfa (ORCID: https://orcid.org/0009-0006-2115-1256)
- Elena Zamagni (ORCID: https://orcid.org/0000-0003-1422-7305)
- Renato Zambello (ORCID: https://orcid.org/0000-0002-8799-5324)
- M. Cavo
- Rachele Freddi (ORCID: https://orcid.org/0000-0002-3490-6439)
- Massimo Offidani (ORCID: https://orcid.org/0000-0003-2749-7347)
- Francesco Berruto
- M. Petrucci
- Gabriele Buda
- Sara Bringhen
- Francesco Di Raimondo
- Pellegrino Musto
Institutions
- University of Padua (IT)
- Policlinico Umberto I (IT)
- IQVIA (United Kingdom) (GB)
- Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari (IT)
- Azienda Ospedaliero-Universitaria di Modena (IT)
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Precision for Medicine (United States) (US)
- Policlinico Universitario di Catania (IT)
- Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- IQ Solutions (US)
- Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" (IT)
- Azienda Ospedaliera Universitaria Pisana (IT)
- University of Bologna (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.3389/fonc.2026.1756247
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00